Journal article
Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma among patients with chronic lymphocytic leukemia
Journal of the American Academy of Dermatology, Vol.83(6), pp.1581-1589
12/2020
DOI: 10.1016/j.jaad.2020.06.1024
PMCID: PMC7669637
PMID: 32682027
Abstract
The incidence of cutaneous squamous cell carcinoma (SCC) in patients with chronic lymphocytic leukemia (CLL) is significantly higher compared with age- and sex-matched controls.
To evaluate the association of factors associated with SCC risk.
Clinical CLL and SCC data were obtained from Mayo Clinic CLL Resource and self-reported questionnaires among patients with newly diagnosed CLL. We computed the CLL International Prognostic Index (CLL-IPI) from CLL prognostic factors, and a polygenic risk score from SCC susceptibility variants. We used Cox regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).
Among 1269 patients with CLL, the median follow-up was 7 years, and SCC subsequently developed in 124 patients. Significant associations with SCC risk were history of skin cancer (HR=4.80; 95% CI: 3.37-6.83), CLL-IPI (HR=1.42; 95% CI: 1.13-1.80), and polygenic risk score (HR=2.58; 95% CI: 1.50-4.43). In a multivariable model, these factors were independent predictors (C statistic = 0.69; 95% CI: 0.62-0.76). T-cell immunosuppressive treatments were also associated with SCC risk (HR=2.29; 95% CI: 1.47-3.55; adjusted for age, sex, and prior SCC).
The sample size decreases when combining all risk factors in a single model.
SCC risk includes history of skin cancer, an aggressive disease at time of CLL diagnosis, receiving T-cell immunosuppressive treatments, and high polygenic risk score. Future studies should develop prediction models that include these factors to improved screening guidelines.
Details
- Title: Subtitle
- Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma among patients with chronic lymphocytic leukemia
- Creators
- Geffen Kleinstern - Mayo ClinicAbdul Rishi - Mercy Medical CenterSara J. Achenbach - Mayo ClinicKari G. Rabe - Mayo ClinicNeil E. Kay - Mayo ClinicTait D. Shanafelt - Stanford UniversityWei Ding - Mayo ClinicJoe F. Leis - Department of Hematology and Oncology, Mayo Clinic, Phoenix, ArizonaAaron D. Norman - Mayo ClinicTimothy G. Call - Mayo ClinicJames R. Cerhan - Mayo ClinicSameer A. Parikh - Mayo ClinicChristian L. Baum - Mayo ClinicSusan L. Slager - Mayo Clinic
- Resource Type
- Journal article
- Publication Details
- Journal of the American Academy of Dermatology, Vol.83(6), pp.1581-1589
- DOI
- 10.1016/j.jaad.2020.06.1024
- PMID
- 32682027
- PMCID
- PMC7669637
- NLM abbreviation
- J Am Acad Dermatol
- ISSN
- 0190-9622
- eISSN
- 1097-6787
- Publisher
- Elsevier Inc
- Grant note
- Acerta Pharma BV P30-CA-15083 / Mayo Clinic Cancer Center P50-CA-97274 / Specialized Programs of Research Excellence R25-CA-92049 / National Cancer Institute (https://doi.org/10.13039/100000054) Octapharma Celgene (https://doi.org/10.13039/100006436) Dermatology Foundation (https://doi.org/10.13039/100001582) MEI Pharma (https://doi.org/10.13039/100016282) R01-CA-92153 / Henry J. Predolin Foundation Agios Pharm Cytomx Therapeutics MorphoSys (https://doi.org/10.13039/501100013650) Pharmacyclics (https://doi.org/10.13039/100014491) Juno Therapeutics (https://doi.org/10.13039/100014561) AstraZeneca CA-97274; CA-235026 / National Cancer Institute (https://doi.org/10.13039/100000054) National Institutes of Health (https://doi.org/10.13039/100000002) Merck (https://doi.org/10.13039/100004334) Janssen Acerta Pharm Sunesis (https://doi.org/10.13039/100015234) Rigel Pharm Pharmacyclics Dava Oncology Career Development Award UL1-TR-000135 / National Center for Advancing Translational Science Tolero Ascentage Pharma Morpho-Sys
- Language
- English
- Date published
- 12/2020
- Academic Unit
- Epidemiology
- Record Identifier
- 9984368085702771
Metrics
3 Record Views